# Study of RiMO-301 and Radiotherapy With PD-1 Inhibitor for the Treatment of Head-Neck Cancer

> **NCT05838729** · PHASE1,PHASE2 · RECRUITING · sponsor: **Coordination Pharmaceuticals, Inc.** · enrollment: 16 (estimated)

## Conditions studied

- Head Neck Cancer
- Intratumoral Injection

## Interventions

- **DRUG:** RiMO-301

## Key facts

- **NCT ID:** NCT05838729
- **Lead sponsor:** Coordination Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-04-03
- **Primary completion:** 2026-09
- **Final completion:** 2026-12
- **Target enrollment:** 16 (ESTIMATED)
- **Last updated:** 2025-09-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05838729

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05838729, "Study of RiMO-301 and Radiotherapy With PD-1 Inhibitor for the Treatment of Head-Neck Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05838729. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*